Universität zu Köln

Pinto, Navin R., Applebaum, Mark A., Volchenboum, Samuel L., Matthay, Katherine K., London, Wendy B., Ambros, Peter F., Nakagawara, Akira, Berthold, Frank, Schleiermacher, Gudrun, Park, Julie R., Valteau-Couanet, Dominique, Pearson, Andrew D. J. and Cohn, Susan L. (2015). Advances in Risk Classification and Treatment Strategies for Neuroblastoma. J. Clin. Oncol., 33 (27). S. 3008 - 3019. ALEXANDRIA: AMER SOC CLINICAL ONCOLOGY. ISSN 1527-7755

Full text not available from this repository.

Abstract

Risk-based treatment approaches for neuroblastoma have been ongoing for decades. However, the criteria used to define risk in various institutional and cooperative groups were disparate, limiting the ability to compare clinical trial results. To mitigate this problem and enhance collaborative research, homogenous pretreatment patient cohorts have been defined by the International Neuroblastoma Risk Group classification system. During the past 30 years, increasingly intensive, multimodality approaches have been developed to treat patients who are classified as high risk, whereas patients with low- or intermediate-risk neuroblastoma have received reduced therapy. This treatment approach has resulted in improved outcome, although survival for high-risk patients remains poor, emphasizing the need for more effective treatments. Increased knowledge regarding the biology and genetic basis of neuroblastoma has led to the discovery of druggable targets and promising, new therapeutic approaches. Collaborative efforts of institutions and international cooperative groups have led to advances in our understanding of neuroblastoma biology, refinements in risk classification, and stratified treatment strategies, resulting in improved outcome. International collaboration will be even more critical when evaluating therapies designed to treat small cohorts of patients with rare actionable mutations. (C) 2015 by American Society of Clinical Oncology

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Pinto, Navin R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Applebaum, Mark A. UNSPECIFIED UNSPECIFIED UNSPECIFIED Volchenboum, Samuel L. UNSPECIFIED UNSPECIFIED UNSPECIFIED Matthay, Katherine K. UNSPECIFIED UNSPECIFIED UNSPECIFIED London, Wendy B. UNSPECIFIED UNSPECIFIED UNSPECIFIED Ambros, Peter F. UNSPECIFIED UNSPECIFIED UNSPECIFIED Nakagawara, Akira UNSPECIFIED UNSPECIFIED UNSPECIFIED Berthold, Frank UNSPECIFIED UNSPECIFIED UNSPECIFIED Schleiermacher, Gudrun UNSPECIFIED UNSPECIFIED UNSPECIFIED Park, Julie R. UNSPECIFIED UNSPECIFIED UNSPECIFIED Valteau-Couanet, Dominique UNSPECIFIED UNSPECIFIED UNSPECIFIED Pearson, Andrew D. J. UNSPECIFIED UNSPECIFIED UNSPECIFIED Cohn, Susan L. UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-392849
DOI:	10.1200/JCO.2014.59.4648
Journal or Publication Title:	J. Clin. Oncol.
Volume:	33
Number:	27
Page Range:	S. 3008 - 3019
Date:	2015
Publisher:	AMER SOC CLINICAL ONCOLOGY
Place of Publication:	ALEXANDRIA
ISSN:	1527-7755
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language STEM-CELL TRANSPLANTATION; PHASE-I TRIAL; REFRACTORY NEUROBLASTOMA; RANDOMIZED-TRIAL; SOLID TUMORS; BONE-MARROW; T-CELLS; CHEMOTHERAPY; MYCN; THERAPY Multiple languages Oncology Multiple languages
URI:	http://kups.ub.uni-koeln.de/id/eprint/39284